AR122901A1 - Composiciones que tienen aplicaciones neuroregenerativas - Google Patents

Composiciones que tienen aplicaciones neuroregenerativas

Info

Publication number
AR122901A1
AR122901A1 ARP210101906A ARP210101906A AR122901A1 AR 122901 A1 AR122901 A1 AR 122901A1 AR P210101906 A ARP210101906 A AR P210101906A AR P210101906 A ARP210101906 A AR P210101906A AR 122901 A1 AR122901 A1 AR 122901A1
Authority
AR
Argentina
Prior art keywords
injury
lactoferrin
neuroregenerative
compositions
applications
Prior art date
Application number
ARP210101906A
Other languages
English (en)
Inventor
Thomas Barnett
David Ross
Original Assignee
Grifols Worldwide Operations Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Grifols Worldwide Operations Ltd filed Critical Grifols Worldwide Operations Ltd
Publication of AR122901A1 publication Critical patent/AR122901A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Urology & Nephrology (AREA)

Abstract

En el presente documento se dan a conocer composiciones farmacéuticas que contienen transferrina y/o lactoferrina para utilizar en la promoción y/o inducción de la generación de nuevas células neurales en un paciente que ha sufrido un evento neurodegenerativo derivado, como mínimo, de una de una lesión cerebral traumática, una lesión cerebral no traumática, una lesión en la médula espinal, una lesión del nervio periférico o una neuropatía periférica. De manera ideal, la transferrina y/o lactoferrina tienen una saturación baja de hierro.
ARP210101906A 2020-07-08 2021-07-07 Composiciones que tienen aplicaciones neuroregenerativas AR122901A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063049516P 2020-07-08 2020-07-08

Publications (1)

Publication Number Publication Date
AR122901A1 true AR122901A1 (es) 2022-10-12

Family

ID=77126776

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210101906A AR122901A1 (es) 2020-07-08 2021-07-07 Composiciones que tienen aplicaciones neuroregenerativas

Country Status (14)

Country Link
US (1) US20230265167A1 (es)
EP (1) EP4178553A1 (es)
JP (1) JP2023532514A (es)
KR (1) KR20230038194A (es)
CN (1) CN115916167A (es)
AR (1) AR122901A1 (es)
AU (1) AU2021305384A1 (es)
BR (1) BR112022026210A2 (es)
CA (1) CA3182956A1 (es)
CL (1) CL2022003596A1 (es)
IL (1) IL299182A (es)
MX (1) MX2022016226A (es)
TW (1) TW202216185A (es)
WO (1) WO2022008586A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4052723A1 (en) * 2021-03-02 2022-09-07 Grifols Worldwide Operations Limited Alpha-1 antitrypsin dosing regimen

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100577798C (zh) * 2007-01-30 2010-01-06 中国人民解放军军事医学科学院基础医学研究所 细胞因子和化合物构成的组方，其促进神经再生作用及在神经系统疾患研究和诊治中的作用
US9376481B2 (en) * 2011-04-26 2016-06-28 The Regents Of The University Of California Methods of promoting CNS neuronal repair by inhibiting LRP-1
EP2776058B2 (en) * 2011-11-11 2019-03-20 Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol Apotransferrin for the treatment of brain stroke
EP3795171B1 (en) 2014-07-11 2024-04-10 Grifols Worldwide Operations Limited Transferrin for use in kidney transplantation

Also Published As

Publication number Publication date
EP4178553A1 (en) 2023-05-17
BR112022026210A2 (pt) 2023-01-17
MX2022016226A (es) 2023-02-01
CA3182956A1 (en) 2022-01-13
WO2022008586A1 (en) 2022-01-13
AU2021305384A1 (en) 2023-02-02
TW202216185A (zh) 2022-05-01
JP2023532514A (ja) 2023-07-28
US20230265167A1 (en) 2023-08-24
CN115916167A (zh) 2023-04-04
CL2022003596A1 (es) 2023-07-07
IL299182A (en) 2023-02-01
KR20230038194A (ko) 2023-03-17

Similar Documents

Publication Publication Date Title
CR20190468A (es) Métodos para tratar enfermedades y trastornos mediados por completo
PE20191303A1 (es) Compuestos con actividad antitumoral contra celulas cancerosas que tienen mutaciones en el exon 20 de egfr o her2
EA201892431A1 (ru) Олигонуклеотиды для лечения заболевания глаз
BR112015006093A2 (pt) combinação de rasagilina e pridopidine para o tratamento de desordens neurodegenerativas, particularmente na doença de huntington
GT201700246A (es) Métodos y kits para tratar la depresión
CL2022003596A1 (es) Composiciones que tienen aplicaciones neuroregenerativas
CO2021014008A2 (es) Compuestos farmacéuticos para el tratamiento de trastornos mediados por complemento
CL2017002846A1 (es) Métodos de tratamiento de trastornos linfoproliferativos asociados al virus de epstein-barr por terapia con células t.
DOP2021000251A (es) Amidas de pirazolo-piridina sustituidas y su uso como moduladores del receptor glun2b
CL2023001580A1 (es) Uso de roluperidona para tratar síntomas y trastornos negativos, aumentar la neuroplasticidad y promover la neuroprotección
CO2020004034A2 (es) Métodos para el tratamiento de distrofia muscular
BR112022019932A2 (pt) Composições para saúde metabólica
EA201800536A1 (ru) Фармацевтическая композиция, которая включает энергетически обработанный нейтральный носитель, и связанные с ним методы лечения
PH12020551179A1 (en) Methods for treating mitochondrial disorder
CL2017001407A1 (es) Antagonista de a2a de dosis baja para el tratamiento de tdah y la enfermedad de parkinson
CO2024000880A2 (es) Compuestos para el tratamiento del dolor, en particular el dolor neuropático, y/u otras enfermedades o trastornos que se asocian con at2r y/o señalización mediada por at2r
CL2022003591A1 (es) Composiciones que tienen aplicaciones neuroregenerativas
CO2023003533A2 (es) Métodos para el tratamiento de trastornos de mineralización ósea referencia cruzada a solicitudes relacionadas
DOP2022000095A (es) Regímenes de dosificación para usar en el tratamiento de la mielofibrosis y trastornos relacionados con nmp con navitoclax
EA202190226A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ HFpEF С ИСПОЛЬЗОВАНИЕМ ДАПАГЛИФЛОЗИНА И СОДЕРЖАЩИХ ЕГО КОМПОЗИЦИЙ
AR110947A1 (es) Tratamiento de degeneración de la retina mediante el uso de células progenitoras
CO2020014399A2 (es) Composiciones farmacéuticas para el tratamiento de la deficiencia de esfingomielinasa ácida
CO2021014968A2 (es) Composición para la prevención o el tratamiento de la caída del cabello que incluye hapln1
MX2021011598A (es) Uso de mir101 o mir128 en el tratamiento de trastornos convulsivos.
BR112023020839A2 (pt) Método in vitro para determinar a eficácia do tratamento de um indivíduo com um distúrbio mental, composição farmacêutica, cápsula e uso de canabidiol ou de uma composição farmacêutica compreendendo canabidiol